ArticleScientific reports2025
Assessment of vivity with French clinical data related to the toric model study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Several types of intraocular lenses (IOLs) can be used during cataract surgery to correct refractive error of the eye. The purpose of this study is to evaluate one of them: AcrySof IQ Vivity toric IOL, a toric implant with extended depth of focus. 27 eyes were implanted with the AcrySof IQ Vivity toric IOL. This prospective study evaluates refractive and visual outcomes and rotational stability at three months after implantation of a toric EDOF IOL, under standardised photopic conditions, uncontrolled. The main objective is to describe the mean corrected visual acuity at 3 months. Secondary objectives are to describe the monocular visual performance of the. IOL and binocular visual performance in patients implanted in both eyes with at least one toric IOL on one side and one toric or non-toric IOL on the other side, as well as patient satisfaction at 3 months. The median monocular DCIVA at 66 cm was 0.16 logMAR (95% CI 0.1 to 0.23), which was comparable to the OUS study of 0.175 logMAR (95% CI 0.148 to 0.202). The spherical equivalent was 0.11 ± 0.31 D (n = 27) and the residual astigmatism was - 0.42 ± 0.25 D 3 months after surgery. The mean monocular values of CDVA, DCIVA, DCNVA and UDVA, UIVA, UNVA were 0.06 ± 0.08, 0.16 ± 0.11, 0.39 ± 0.14 and 0.07 ± 0.08, 0.20 ± 0.15, 0.46 ± 0.2 logMAR, respectively. IOL rotation was 3.52 ± 2.87 degrees, with 86% of subjects undergoing IOL rotation ≤ 5°. Among the 27 patients who received bilateral Vivity implants, including at least one toric Vivity implant, 81% of the subjects never or rarely needed glasses at intermediate distance in bright light. 41% of the patients reported no glare and 48% no halos. AcrySof IQ Vivity toric IOL achieves good intermediate vision refractive results comparable to those of the OUS study evaluating Vivity DFT015, with good rotational stability.Trial registration the study was registered with the French Clinical Register (NCT: 05416177).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.